RxDoctor Payments Data

Megan Suh, APRN

Nurse Practitioner · North Platte, NENPI 1235616368

Payments from drug & device makers

$521in general payments, 2019–2025

Across 21 payments — averaging $24.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$286
  • Regeneron Healthcare Solutions, Inc.$53
  • Verona Pharma, Inc.$47
  • United Therapeutics Corporation$47
  • GSK$21
  • Insmed, Inc.$20
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$521100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$521 in reported general payments places this provider in the 60th percentile of 924 nurse practitioner providers in Nebraska.

See all nurse practitioner providers in Nebraska

Medicare billing

Part B allowed, 2024
$1,490
Medicare patients
20
Services billed
21

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter102$68,440
Stiolto RespimatTiotropium Br/Olodaterol Hcl63$29,699
Breo ElliptaFluticasone/Vilanterol71$29,539
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr58$28,954
Spiriva RespimatTiotropium Bromide43$26,097
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$17,428
Incruse ElliptaUmeclidinium Bromide30$11,366
Bevespi AerosphereGlycopyrrolate/Formoterol Fum25$9,317
DuleraMometasone/Formoterol12$3,922
Arnuity ElliptaFluticasone Furoate13$3,726
Albuterol Sulfate HfaAlbuterol Sulfate98$2,888
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$2,464
Ventolin HfaAlbuterol Sulfate38$2,103
Prednisone26$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$21$142,024274 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$18$55,797106 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere$286$26,74548 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 924 nurse practitioner providers in Nebraska.

Other nurse practitioner in North Platte

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →